1. Home
  2. NVCR vs MSDL Comparison

NVCR vs MSDL Comparison

Compare NVCR & MSDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NVCR
  • MSDL
  • Stock Information
  • Founded
  • NVCR 2000
  • MSDL 2019
  • Country
  • NVCR Jersey
  • MSDL United States
  • Employees
  • NVCR N/A
  • MSDL N/A
  • Industry
  • NVCR Medical/Dental Instruments
  • MSDL
  • Sector
  • NVCR Health Care
  • MSDL
  • Exchange
  • NVCR Nasdaq
  • MSDL NYSE
  • Market Cap
  • NVCR 1.8B
  • MSDL 1.8B
  • IPO Year
  • NVCR 2015
  • MSDL N/A
  • Fundamental
  • Price
  • NVCR $17.49
  • MSDL $19.91
  • Analyst Decision
  • NVCR Buy
  • MSDL Buy
  • Analyst Count
  • NVCR 5
  • MSDL 7
  • Target Price
  • NVCR $26.60
  • MSDL $21.67
  • AVG Volume (30 Days)
  • NVCR 1.3M
  • MSDL 407.4K
  • Earning Date
  • NVCR 10-30-2024
  • MSDL 01-01-0001
  • Dividend Yield
  • NVCR N/A
  • MSDL 7.50%
  • EPS Growth
  • NVCR N/A
  • MSDL N/A
  • EPS
  • NVCR N/A
  • MSDL N/A
  • Revenue
  • NVCR $549,964,000.00
  • MSDL N/A
  • Revenue This Year
  • NVCR $16.23
  • MSDL $1,597.39
  • Revenue Next Year
  • NVCR $6.09
  • MSDL $14.28
  • P/E Ratio
  • NVCR N/A
  • MSDL N/A
  • Revenue Growth
  • NVCR 8.33
  • MSDL N/A
  • 52 Week Low
  • NVCR $10.87
  • MSDL $19.05
  • 52 Week High
  • NVCR $24.74
  • MSDL $24.18
  • Technical
  • Relative Strength Index (RSI)
  • NVCR 43.24
  • MSDL 52.37
  • Support Level
  • NVCR $15.61
  • MSDL $19.48
  • Resistance Level
  • NVCR $17.31
  • MSDL $20.39
  • Average True Range (ATR)
  • NVCR 1.29
  • MSDL 0.34
  • MACD
  • NVCR 0.05
  • MSDL 0.02
  • Stochastic Oscillator
  • NVCR 11.59
  • MSDL 69.06

About NVCR NovoCure Limited

NovoCure Ltd serves in the healthcare sector of the United States. Its business involves the development, manufacture and commercialization of Tumor Treating Fields (TTFields) devices, including Optune Gio and Optune Lua, for the treatment of solid tumor cancers. Its pipeline consists of Trident, Lunar-2, Panova-3, Metis and other products and technologies for the treatment of Glioblastoma, Non-smell cell lung cancer and Pancreatic cancer. Geographically, the company derives majority of its revenue from the United States and rest from Germany, Japan and other markets.

About MSDL MORGAN STANLEY DIRECT LENDING FUND

Morgan Stanley Direct Lending Fund is a fund whose investment objective is to achieve attractive risk-adjusted returns via current income and, to a lesser extent, capital appreciation by investing predominantly in directly originated senior secured term loans issued by U.S. middle-market companies backed by private equity sponsors. It invests predominantly in directly originated senior secured term loans including first lien senior secured term loans including unitranche loans and second lien senior secured term loans, with the balance of the investments expected to be in higher-yielding assets such as mezzanine debt, unsecured debt, equity investments and other opportunistic asset purchases.

Share on Social Networks: